Gilead Sciences Executive and Leadership Team

Andrew Dickinson, the Chief Financial Officer at Gilead Sciences, directs the global financial strategy and capital allocation processes. Managing the fiscal health of the organization, the Chief Financial Officer oversees long-term investment planning, investor relations, and financial reporting across international markets. This leadership role requires constant alignment with the research and development pipeline to ensure sustainable funding for high-impact pharmaceutical projects. By optimizing the balance sheet, Andrew Dickinson supports the expansion of the oncology and viral disease portfolios. The Chief Financial Officer also manages complex collaboration agreements with external biotech partners to accelerate drug discovery. Through rigorous financial oversight, Dickinson secures the resources necessary for maintaining a competitive edge in the biopharmaceutical sector. This executive function remains vital for sustaining the growth trajectory of the company while delivering consistent value to shareholders and patients worldwide.

Srihari Narasimhan, the Strategic Initiatives Lead & To The Chief of Staff & Chief Financial Officer at Gilead Sciences, directs the execution of key corporate projects that support financial and operational objectives. Overseeing the integration of strategic planning with daily administrative functions, the Strategic Initiatives Lead & To The Chief of Staff & Chief Financial Officer ensures that the executive office remains focused on high-priority business outcomes. This role involves analyzing performance metrics to identify opportunities for operational improvement across the company. By facilitating communication between the finance department and other business units, Srihari Narasimhan drives alignment on critical growth initiatives. The Strategic Initiatives Lead & To The Chief of Staff & Chief Financial Officer also manages the preparation of executive briefings for the board of directors. Through this coordination, Narasimhan supports the leadership team in making data-driven decisions that advance the company's mission in the global biopharmaceutical market.

Deborah Son, the Chief Marketing Officer, Supply Chain at Gilead Sciences, architects the commercial distribution strategies for critical HIV and viral hepatitis medications. Overseeing the integration of marketing initiatives with global supply chain logistics, the Chief Marketing Officer, Supply Chain ensures that life-saving treatments reach patients across North America, Europe, and international territories. This role involves coordinating with manufacturing teams to maintain inventory levels for products like Biktarvy and Veklury. By analyzing market demand patterns, Deborah Son drives the efficiency of the distribution network to minimize supply disruptions. The Chief Marketing Officer, Supply Chain also collaborates with regional sales leaders to refine product positioning in diverse healthcare environments. Through this dual focus on market penetration and operational reliability, Son strengthens the commercial footprint of the company. This leadership position directly impacts the accessibility of essential medicines for patients facing serious health challenges.

Naomi Bautista, the Gain Chief of Staff (Gilead Asian Interest Network) at Gilead Sciences, directs internal initiatives that foster diversity and inclusion within the corporate culture. Overseeing the strategic alignment of the Gilead Asian Interest Network with broader organizational goals, the Gain Chief of Staff (Gilead Asian Interest Network) promotes professional development and community engagement. This leadership role involves facilitating communication between employee resource groups and executive management to ensure diverse perspectives inform corporate decision-making. By championing inclusive workplace practices, Naomi Bautista supports the retention of top talent across the global workforce. The Gain Chief of Staff (Gilead Asian Interest Network) also coordinates events and programs that highlight the contributions of Asian employees to the company's scientific and commercial success. Through these efforts, Bautista strengthens the internal culture, ensuring that the company remains an employer of choice while advancing its mission to improve global health outcomes.

Susanna Stinson, the Director, Research Chief of Staff and Strategic Projects at Gilead Sciences, manages the operational workflows within the research and development division. Overseeing the execution of high-priority scientific projects, the Director, Research Chief of Staff and Strategic Projects ensures that laboratory efforts align with the company's long-term drug discovery goals. This role involves coordinating cross-functional teams to streamline the transition of candidates from early-stage research into clinical trials. By optimizing project management processes, Susanna Stinson accelerates the development of novel therapies for oncology and invasive fungal infections. The Director, Research Chief of Staff and Strategic Projects also facilitates communication between research scientists and the executive leadership team to prioritize resource allocation. Through rigorous project oversight, Stinson ensures that the research pipeline remains robust and responsive to emerging medical needs. This leadership function remains essential for maintaining the company's position as a leader in biopharmaceutical innovation.

Courtney Desmond, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer at Gilead Sciences, directs the operational activities of the ethics and compliance department. Overseeing the implementation of regulatory standards across global operations, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer ensures that all commercial and research activities adhere to strict legal and ethical guidelines. This role involves managing internal audits, policy development, and training programs to mitigate corporate risk. By fostering a culture of integrity, Courtney Desmond supports the company's reputation in the highly regulated pharmaceutical industry. The Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer also coordinates with legal teams to address complex compliance challenges in international markets. Through these efforts, Desmond ensures that the organization maintains the highest standards of conduct while pursuing its mission to deliver innovative medicines to patients worldwide.

Erik Schroeppel, the Chief Marketing Officer, Supply Chain & Manager at Gilead Sciences, directs the management of supply chain operations for oncology and pulmonary arterial hypertension products. Overseeing the coordination between marketing strategy and manufacturing output, the Chief Marketing Officer, Supply Chain & Manager ensures that the company maintains a reliable supply of essential medications for patients. This role involves managing vendor relationships and optimizing logistics networks to support global market expansion. By implementing advanced inventory management systems, Erik Schroeppel improves the efficiency of the product delivery cycle. The Chief Marketing Officer, Supply Chain & Manager also collaborates with regional sales teams to ensure that product availability meets the specific needs of healthcare providers. Through these operational efforts, Schroeppel supports the company's ability to deliver consistent patient care. This leadership position remains critical for maintaining the integrity of the supply chain in a complex, international regulatory environment.

Sonja Tong, the Executive Director and Chief of Staff at Gilead Sciences, directs the administrative and strategic operations of the executive office. Overseeing the prioritization of corporate initiatives, the Executive Director and Chief of Staff ensures that leadership efforts remain focused on the company's core mission of discovering and commercializing life-saving medicines. This role involves managing complex cross-functional projects that require collaboration across research, commercial, and legal departments. By streamlining communication and decision-making processes, Sonja Tong enhances the overall efficiency of the leadership team. The Executive Director and Chief of Staff also coordinates the development of long-term organizational goals to address unmet medical needs in the United States and internationally. Through these efforts, Tong supports the executive team in navigating the challenges of the biopharmaceutical industry. This leadership function remains vital for maintaining organizational alignment and driving the company's strategic growth in a competitive global market.

Brenda Hoffman, the HIV Division at Gilead Sciences, directs the strategic development and commercialization of the company's extensive portfolio of HIV/AIDS treatments. Overseeing the lifecycle management of products like Biktarvy and Genvoya, the HIV Division ensures that these therapies remain accessible to patients globally. This role involves coordinating with clinical research teams to evaluate new treatment options and with commercial teams to expand market reach. By analyzing patient outcomes and healthcare trends, Brenda Hoffman drives the innovation of the HIV treatment pipeline. The HIV Division also manages key partnerships with external organizations to advance research into long-acting therapies and potential cures. Through these efforts, Hoffman supports the company's commitment to ending the HIV epidemic. This leadership position remains essential for maintaining the company's market-leading position in the viral disease space while addressing the evolving needs of patients and healthcare providers across international markets.